Guest guest Posted September 9, 2011 Report Share Posted September 9, 2011 PSI-7977 with Standard Therapy Produces 91% Sustained ResponseThe experimental hepatitis C virus (HCV) nucleotide analog polymerase inhibitor PSI-7977, used in combination with pegylated interferon and ribavirin, demonstrated a 12-week sustained virological response rate of 91% for previously untreated genotype 1 chronic hepatitis C patients in the ongoing PROTON trial.HALT-C Finds High Rate of Liver-Related Death and Transplants among Interferon Non-RespondersChronic hepatitis C patients in the HALT-C study who did not achieve sustained response to standard combination therapy or long-term pegylated interferon monotherapy had a high rate of liver transplantation and liver-related death, researchers reported in the August 2011 issue of Hepatology. Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 9, 2011 Report Share Posted September 9, 2011 PSI-7977 with Standard Therapy Produces 91% Sustained ResponseThe experimental hepatitis C virus (HCV) nucleotide analog polymerase inhibitor PSI-7977, used in combination with pegylated interferon and ribavirin, demonstrated a 12-week sustained virological response rate of 91% for previously untreated genotype 1 chronic hepatitis C patients in the ongoing PROTON trial.HALT-C Finds High Rate of Liver-Related Death and Transplants among Interferon Non-RespondersChronic hepatitis C patients in the HALT-C study who did not achieve sustained response to standard combination therapy or long-term pegylated interferon monotherapy had a high rate of liver transplantation and liver-related death, researchers reported in the August 2011 issue of Hepatology. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.